Nature
-
Randomized Controlled Trial Multicenter Study
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans.
The Ad26. COV2. S vaccine1-3 has demonstrated clinical efficacy against symptomatic COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing antibodies1. ⋯ COV2. S were reduced against the B.1.351 and P.1 variants, but functional non-neutralizing antibody responses and T cell responses were largely preserved against SARS-CoV-2 variants. These findings have implications for vaccine protection against SARS-CoV-2 variants of concern.